Amping up With PemJAK

• Status: RECRUITING
• Trial end date: 2029-01-01

Summary

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

• Phase: PHASE2

Details

• Lead Sponsor: Seda S. Tolu
• Collaborator: Incyte Corporation
• Treatments: pembrolizumab; ruxolitinib